Indivior Plc (INDV.US) has confirmed plans to move its primary listing to New York this summer and will ask shareholders to approve the decision next month.
The British drugmaker, which makes opioid addiction treatments Suboxone and Sublocade, said shareholders had expressed support for the move, which would retain London as a secondary listing location for Indivior.
Indivior is one of a series of UK-listed companies that have announced plans to shift their primary listing venue to New York.
A deeper pool of investor capital, looser regulatory rules and higher levels of executive compensation have lured companies such as Flutter Entertainment (FLUT) and CRH Plc (CRH) to look across the Atlantic.
Indivior said first-quarter sales of Sublocade were impacted by a cyberattack on the largest U.S. medical claims processor and the de-enrollment of Medicaid patients.
The company\’s net revenue for the quarter rose 12% to $284 million, according to compiled data, but fell short of analysts\’ expectations.
British opioid withdrawal drug maker Indivior confirms relocation of primary launch site to New York
The British drugmaker, which makes opioid addiction treatments Suboxone and Sublocade, said shareholders had expressed support for the move, which would retain London as a secondary listing location for Indivior.
Like (0)
Some banks have made a big move: the interest rate on RMB deposits is 18.1%
Previous
April 25, 2024 6:10 pm
Pre-market: Nasdaq futures fell 0.9%, Meta fell more than 14.5%
Next
April 25, 2024 7:59 pm